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Epithelial to mesenchymal transdifferentiation is a novel
mechanism that promotes renal fibrosis and here we
investigated whether known causes of renal fibrosis
(angiotensin II and transforming growth factor b, TGFb) act
through this pathway. We infused angiotensin II into rats for
1 day and found that it activated the Smad pathway which
persisted for up to 2 weeks in chronically infused rats. Renal
TGF-b mRNA expression was increased at 3 days and its
protein at 2 weeks suggesting Smad pathway activation
occurred earlier than TGF-b upregulation. In cultured human
tubuloepithelial cells, angiotensin II caused a rapid activation
of Smad signaling independent of TGF-b however,
Smad-dependent transcription after 1 day was TGF-b
mediated. Two weeks of angiotensin II infusion activated
genes associated with epithelial mesenchymal
transdifferentiation. Stimulation with angiotensin II for
3 days caused transdifferentiation of the cultured epithelial
cells by TGF-b-mediated processes; however, early
changes were independent of endogenous TGF-b.
Smad7 overexpression, which blocks Smad2/3 activation,
diminished angiotensin II-induced epithelial mesenchymal
transdifferentiation. Our results show that angiotensin II
activates the Smad signaling system by TGF-b-independent
processes, in vivo and in vitro, causing renal fibrosis.
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Activation of local renin–angiotensin system has been found
in many kidney diseases. Angiotensin II (AngII), the main
peptide of the renin–angiotensin system, contributes to the
progression of renal damage.1 This peptide activates
tubuloepithelial cells, interstitial fibroblasts, and glome-
rular cells, regulating cell growth and extracellular matrix
synthesis.1–3 Many studies have demonstrated that AngII
participates in renal fibrosis through endogenous production
of growth factors.1–4 The relation between AngII and
transforming growth factor-b (TGF-b) in renal fibrosis is
already known.3 TGF-b transmits signals to the nuclei
through the activation of the Smad pathway.5,6 TGF-b binds
to type II receptor, which activates the type I receptor kinase,
which in turn phosphorylates the receptor-regulated Smads
(R-Smads), Smad2 and Smad3, at C-terminal serines. The
R-Smads then dissociate from the receptor complex to form
a heterotrimeric complex with Smad4. These complexes
translocate to the nucleus and function as transcriptional
regulators of target genes. The inhibitory Smad7 binds to
activated type I receptor, thereby preventing Smad2/3
phosphorylation, or recruits the ubiquitine ligases Smurf1
and Smurf2 to induce proteasomal degradation.5,6 In renal
cells, Smads participate in TGF-b-induced epithelial–
mesenchymal transdifferentiation (EMT) and fibrosis.6,7
The angiotensin type I receptor (AT1) blockade diminishes
Smad pathway activation in myocardial infarction in rats
and in an experimental model of renal damage.8,9 We have
described that in vascular smooth muscle cells (VSMCs),
AngII activates the Smad signaling pathway independently
of TGF-b and linked to vascular fibrosis.10 However, there
are no studies investigating whether AngII activates the
Smad signaling pathway in the kidney and its potential role
in EMT.
Tubulointerstitial fibrosis is a final common pathway to
end-stage chronic kidney diseases, and its severity correlates
with renal prognosis. Many evidences suggest that renal
tubuloepithelial cells can undergo EMT to become matrix-
producing fibroblasts under pathologic conditions and,
therefore, participate in the pathogenesis of chronic renal
diseases. Cytokines, growth factors, adhesion molecules, and
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changes in the extracellular matrix composition are involved
in EMT.11–13 TGF-b has been described as the most potent
inducer of fibrosis and EMT.5,7,11,14 In cultured tubulo-
epithelial cells, AngII induces a-smooth muscle actin
(a-SMA) expression and mesenchymal features.15 Infusion
of AngII into rats causes tubular injury associated with
neoexpression of a-SMA and vimentin in renal interstitial
cells;16,17 therefore, it is reasonable to speculate that AngII
could be involved in EMT in the kidney.
The aim of this work was to investigate whether AngII
activates the Smad pathway in the kidney and its role in EMT,
evaluating the involvement of endogenous TGF-b synthesis
in these processes.
RESULTS
Systemic AngII infusion into rats activates the Smad
pathway in the kidney
One of the initial steps of Smad activation is the phos-
phorylation of R-Smads.5,6 We have investigated whether
AngII in vivo could activate the Smad pathway in the kidney
by evaluation of the time course evolution of R-Smad
phosphorylation. In AngII-treated rats for 24 h total renal
phosphorylated, Smad3 levels were significantly increased
compared with control animals (western blot, Figure 1a),
indicating a rapid Smad activation in the kidney. After 3 days,
phosphorylated-Smad2/3 (p-Smad2/3) markedly appeared
in the nucleus of tubuloepithelial cells (Figure 1b). Similar
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Figure 1 | AngII infusion activates the Smad pathway in the kidney. Rats were infused with AngII (100 ng/kg/min) from 24 h to 2 weeks
and phosphorylated levels of Smad proteins were evaluated by (a, c) western blot and (b) immunohistochemistry. In western blot,
phosphorylated-Smad3 (p-Smad3) levels were evaluated in renal protein extracts. Panels (a) and (c) show a representative experiment on
the right panel and data as mean±s.e.m. of 4–6 animals per group on the left. *Po0.05 vs control. Panel (b) shows a representative
experiment of pSmad2/3 immunohistochemistry on the right and the quantification of data as mean±s.e.m. of 4–6 animals per group on
the left. (d) By Southwestern histochemistry, active Smad complexes, shown by nuclear blue staining (marked by arrows), were detected
in AngII-infused rats for 2 weeks. The figure shows a representative experiment of three animals studied in each group on the right panel
and data as mean±s.e.m. of 4–6 animals per group on the left. *Po0.05 vs control. Original magnification  200.
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results were found with the antibody that recognizes only p-
Smad3 (not shown). The Smad pathway remained activated
in chronic AngII-infused rats, as shown by western blot
(Figure 1c) and by Southwestern histochemistry, a technique
that allows to detect Smad–DNA binding activity in paraffin-
embedded tissues.18 In AngII-infused rats for 2 weeks, active
Smad complexes were observed in some glomerular and
tubuloepithelial cells, whereas only a few positive cells were
found in control animals (Figure 1d).
AngII-induced Smad activation occurs earlier than TGF-b
production. To investigate whether Smad activation was
directly induced by AngII or mediated by endogenous TGF-b
synthesis, we have evaluated TGF-b mRNA and protein levels
at different time points. AngII did not increase renal TGF-b
mRNA levels after 24 h, but this gene was upregulated at
72 h and remained elevated after 2 weeks (real time PCR,
Figure 2a). TGF-b is synthesized as an inactive protein, which
is anchored to the cell membrane before activation.6 In
cultured cells, AngII increases TGF-b mRNA expression,
protein production, and activation of latent TGF-b, the latter
regulated by a thrombospondin-1 mediated process.19 In rats
that have been AngII-treated for 72 h, throsmbospondin-1
mRNA levels were not upregulated compared with controls
(real-time PCR, not shown). Moreover, in these animals,
there was no increase in TGF-b protein levels, which were
dramatically overexpressed after 2 weeks of AngII infusion
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Figure 2 | Renal TGF-b expression is upregulated in chronic, but not acute, AngII infusion. Renal gene and protein expression levels
of TGF-b were evaluated at different time points of AngII infusion. Panel (a) shows data of real-time PCR experiments as mean±s.e.m.
of 6–8 animals per group. *Po0.05 vs control. Panel (b) shows a representative experiment evaluated by western blot on the right panel and
data as mean±s.e.m. of 4–6 animals per group on the left. *Po0.05 vs control. Panel (c) shows a representative experiment of TGF-b
immunohistochemistry. (d) Renal gene expression of EMT markers and Smad proteins in AngII-infused rats for 2 weeks. The figure
shows data of real-time PCR experiments of Smad4, Smad7, E-cadherin, a-SMA, and vimentin gene expressions as mean±s.e.m. of
6–8 animals per group. *Po0.05 vs control.
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(Figure 2b and c). These data indicate that Smad activation
(observed at 24 h) occurs before the increase in TGF-b
synthesis (observed after 72 h), suggesting that AngII in vivo
directly activates Smad pathway in the kidney.
Chronic infusion of AngII into rats induces EMT in the
kidney. By means of real-time PCR, we have analyzed the
renal expression of the mesechymal marker a-SMA at
different time points of AngII infusion, and only after 2
weeks, a-SMA mRNA was upregulated. In these animals,
vimentin was not modified and the epithelial marker E-
cadherin was downregulated (Figure 2d). Renal gene
expressions of Smad4 and Smad7 were also increased in
AngII-infused rats compared with controls, indicating
upregulation of Smads expression (Figure 2d). These data
show that chronic infusion of AngII into rats causes renal
fibrosis, associated with induction of EMT, overexpression of
TGF-b, and activation of the Smad pathway.
AngII activates the Smad pathway in cultured human
tubuloepithelial cells
To further demonstrate a direct effect of AngII in Smad
pathway, in vitro studies were carried out in cultured human
tubuloepithelial cells (HK2 cell line). In these cells, stimula-
tion with AngII and TGF-b (1 ng/ml) induced a rapid
phosphorylation of R-Smads at 15 min of incubation,
demonstrated by a significant increase in nuclear levels of
phosphorylated Smad2 and Smad3 (Figure 3a, western blot).
By confocal microscopy, we have observed that, in growth-
arrested HK2 cells, Smads proteins are located in the cytosol,
as demonstrated using indirect immunofluorescency for
Smad4 (Figure 3b). Treatment with AngII for 15 min
increased total p-Smad2 staining and caused the nuclear
translocation of p-Smad2 and Smad4 (Figure 3b).
In the nucleus, the R-Smad/Smad4 complex can activate
transcription through direct binding to certain DNA
sequences.6 In tubuloepithelial cells, AngII increased DNA-
binding activity to the CAGA box as early as at 10 min, with a
maximal response at 15 min (3.5-fold, Po0.05 vs control,
n¼ 3 electrophoretic mobility shift assay experiments). The
same was observed with TGF-b (Figure 4a). The specific
Smad complexes were detected by competition assays with a
100-fold excess of unlabeled or mutant CAGA box (marked
by arrows in Figure 4a). By supershift assays, we have
observed that the antibodies against Smad2 and Smad4, alone
or in combination, shifted the band to a higher molecular
weight (Supershifted bands marked by arrows), supporting
the involvement of Smad2 in AngII responses (Figure 4b).
We have investigated whether AngII regulates Smad-
mediated gene expression by transient transfection with a
luciferase Smad reporter plasmid (Smad/luc), which contains
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Figure 3 | AngII induces a rapid activation of Smad pathway in cultured human tubuloepithelial cells. Cells treated with 107 mol/l
AngII or 1 ng/ml TGF-b for 15 min. (a) AngII induces Smad2/3 phosphorylation. Total protein levels of phosphorylated-Smad2 (p-Smad2)
and p-Smad3 were quantified by western blot. The figure shows a representative experiment on the right panel and data as mean±s.e.m.
of three experiments on the left. *Po0.05 vs control. (b) AngII causes the nuclear translocation of Smad4 and p-Smad2. The evaluation
of Smad4 and p-Smad2 was done by confocal microscopy with fluorescein isothiocyanate-labeled secondary antibodies (green staining).
Nuclei were stained with propidium iodide (in red). In the merge of FITC and PI staining, the yellow staining indicates nuclear localization
of Smads proteins. The results are representative of three independent experiments.
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four copies of the recognition site for the Smad sequence.
After 24 h of incubation with AngII, the Smad promoter
activity was increased (1.5-fold, Po0.05 vs control, n¼ 4
experiments).
Mechanisms involved in AngII-induced Smad activation in
cultured human tubuloepithelial cells
AngII rapidly activates Smad pathway by a TGF-b-independent
mechanism. To block TGF-b, we used two different
strategies: a neutralizing antibody against active TGF-b,
which blocks AngII-induced extracellular matrix produc-
tion,4 and the SB431542 compound, an inhibitor of the
activin receptor-like kinase 5.20 In HK2 cells, the blockade of
TGF-b did not modify AngII-induced Smad2/3 phosphory-
lation (Figure 5a) or their nuclear translocation (Figure 5b
and not shown) observed after 15 min of incubation. Similar
results were found in the regulation of Smad DNA-binding
activity in cells treated with AngII for 15 min (not shown).
These data show that early Smad activation by AngII is
independent of endogenous TGF-b production or activation.
TGF-b mediates late activation of Smad pathway caused by
AngII. The blockade of TGF-b diminished Smad-dependent
transcription observed after 24 h of incubation with AngII
(Figure 5c), suggesting that TGF-b is involved in long-term
Smad activation.
Mitogen-activated protein kinase signaling mediates AngII-
induced Smad activation. Previous studies in VSMCs have
demonstrated a cross-talk between Smad and mitogen-
activated protein kinase (MAPK) pathways,10,21 but there
are no studies in renal cells. The involvement of MAPKs
cascade was evaluated using specific inhibitors of p38-MAPK
(SB203580), extracellular signal-regulated kinase1/2 (ERK)
(PD98059) and Jun N-terminal kinase (JNK) (SP600125)
pathways.22,23 We have found that in HK2 cells
all three MAPK inhibitors (p38, ERK, and JNK) signifi-
cantly diminished AngII-induced Smad2 phosphorylation
(Figure 5d).
AngII causes EMT via AT1 receptors in cultured human
tubuloepithelial cells
Incubation with AngII for 3 days causes phenotypic
conversion of HK2 cells. The transformed cells lost the
typical cobblestone pattern of an epithelial monolayer and
displayed a spindle-shaped, fibroblast-like morphology,
assessed by phase contrast microscopy (Figure 6a). This
effect was more marked after 5 days. AngII induced de novo
protein expression of a-SMA and vimentin at 24 h and
remaining elevated after 3 days. This was accompanied by
the loss of the epithelial marker E-cadherin, essential for
the structural integrity of renal epithelium (western blot;
Figure 6b). In unstimulated tubuloepithelial cells, no staining
for vimentin or a-SMA was observed by confocal microscopy.
Treatment with AngII for 3 and 5 days induced vimentin
and a-SMA-positive microfilaments in the cytoplasm, and
E-cadherin immunostaining disappeared (Figure 6c). These
data suggest that tubuloepithelial cells, stimulated with
AngII, undergo a conversion process into myofibroblasts.
Pre-incubation of HK2 cells with the specific AT1
antagonist valsartan blocked AngII-induced vimentin expres-
sion and changes in cell morphology (Figure 6d and e). These
results suggest that AngII-induced EMT was mediated by
AT1 receptors.
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Figure 4 | AngII increases Smad DNA-binding activity in human tubuloepithelial cells. (a) HK2 cells were incubated with 107 mol/l
AngII or 1 ng/ml TGF-b for 10 min. Smad activity was determined by electrophoretic mobility shift assay. Competition assays with a 100-fold
excess of unlabeled or mutant CAGA box show specific Smad complexes (marked by arrows). (b) Identification of Smad complexes induced
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Role of endogenous TGF-b on AngII-induced EMT
TGF-b is a mediator of AngII-induced fibrosis. The effects
of AngII and TGF-b at 24 h on the regulation of EMT
markers were similar (Figure 6). We therefore tested whether
early AngII-induced EMT was TGF-b independent by
evaluating vimentin expression. In HK2 cells, vimentin
induction caused by AngII after 18 and 24 h of incubation
was not diminished by the endogenous blockade of TGF-b
(Figure 7a), suggesting that the initial induction of EMT is
independent of TGF-b. However, TGF-b blockers signifi-
cantly diminished AngII-induced vimentin expression after 3
days, as well as the phenotypic conversion to fibroblast-like
morphology (Figure 7b and c), suggesting that TGF-b
contributes to the progression of the EMT process caused
by AngII.
AngII-induced EMT is mediated by Smad activation
To block Smad actions, cells were transiently transfected with
a Smad7 expression vector that inhibits TGF-b/Smad-
mediated transcriptional effects by interfering with recep-
tor-mediated activation of R-Smad.14 HK2 cells transfected
with Smad7 markedly diminished EMT caused by AngII
and TGF-b. Overexpression of Smad7 inhibited vimentin
upregulation caused by both AngII and TGF-b after 24 h,
compared with cells transfected with an empty vector,
pcDNA3B (western blot; Figure 8a). By immunofluorescence,
we observed that Smad7 overexpression impaired AngII-
mediated changes in cell shape and induction of a-SMA
staining after 3 days (Figure 8b), as observed with TGF-b,
whereas cells transfected with pcDNA3B undergo EMT in
response to both stimuli.
DISCUSSION
We have evaluated the effect of AngII on the Smad signaling
pathway in the kidney. Our in vivo studies using the model of
systemic infusion of AngII showed the activation of the Smad
pathway as early as 24 h and remained elevated until 2 weeks.
AngII-treated rats presented increased renal levels of
phosphorylated Smad2/3 proteins and active Smad com-
plexes, mainly in tubuloepithelial cells and in some
glomerular cells. In cultured human tubuloepithelial cells,
AngII caused a rapid activation of Smad pathway (observed
at 15 min of incubation), showed by increased Smad2/3
phosphorylation, nuclear translocation of phosphorylated
Smad2 and Smad4, and increased DNA-binding activity to
CAGA-box oligonucleotide. Our data demonstrate that AngII
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Figure 5 | AngII activates early Smad pathway independently of TGF-b in human tubuloepithelial cells. TGF-b was blocked by
pretreatment with 10 mg/ml TGF-b neutralizing antibody or 105 mol/l SB431542 for 1 h, before AngII (107 mol/l) stimulation for 15 min.
(a) Nuclear protein levels of phosphorylated-Smad2/3 were quantified by western blot. The figure shows a representative experiment on
the right panel and data as mean±s.e.m. of three experiments on the left. (b) The p-Smad2 was located by indirect immunofluorescence
with a fluorescein isothiocyanate-labeled secondary antibody (green staining). The figure is representative of three experiments.
(c) AngII-induced long-term Smad activation is mediated by TGF-b. HK2 cells were transfected with Smad/luc promoter and TK-renilla.
After 24 h serum-starvation, TGF-b was blocked and cells were stimulated with AngII for 24 h. Then luciferase/renilla activity was measured.
Data of mean±s.e.m. of four experiments done in triplicate is shown. (d) MAPK activation is involved in AngII-induced Smad activation.
HK2 cells were pretreated with 106 mol/l SB203580 (p38 inhibitor), 105 mol/l PD98059 (ERK p42/44 inhibitor), or 105 mol/l SP600125
(JNK inhibitor) for 1 h, before treatment with 107 mol/l AngII for 15 min. Nuclear and cytosolic fractions were extracted and levels of
p-Smad2 were evaluated by western blot. Red ponceau staining was used as loading control. Panel (d) shows a representative experiment
in the top panel and data of mean±s.e.m. of three experiments in bottom panel. *Po0.05 vs control. #Po0.05 vs AngII.
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activates the Smad signaling in the kidney in vivo and in
cultured human tubuloepithelial cells.
In the kidney, there is an interesting link between AngII
and TGF-b. Angiotensin-converting enzyme inhibitors or AT
receptor antagonists diminish renal expression of TGF-b and
fibrosis.3 In cultured renal cells, AngII stimulates TGF-b
expression, and the blockade of TGF-b diminishes some
AngII responses, including extracellular matrix regulation.2,3
Infusion of AngII into rats also increased renal TGF-b
synthesis.24 However, we have found that AngII-induced
Smad activation (observed at 24 h) occurs earlier than TGF-b
upregulation (observed after 72 h in gene expression and later
on in protein levels). These data suggest that in the kidney
AngII causes a rapid activation of the Smad pathway by a
TGF-b-independent mechanism. To further demonstrate
whether the AngII effect was independent of endogenous
TGF-b production, in vitro studies were done. Firstly, we
have compared the time-course response of Smad activation
and TGF-b induction. In tubuloepithelial cells, AngII
only increases TGF-b production after 24 h of incubation
(data not shown), whereas Smad activation was found after
15 minutes of AngII stimulation. Secondly, we blocked
TGF-b using a neutralizing antibody against active TGF-b
and an inhibitor of TGF-b receptor. The blockade of endo-
genous TGF-b did not alter nuclear translocation of phos-
phorylated Smad2 and Smad4 and Smad DNA-binding
activity observed after 15 min of incubation with AngII,
showing a TGF-b-independent Smad signaling activation.
However, TGF-b mediates late activation of Smad pathway,
because TGF-b blockers diminished AngII-induced Smad-
dependent transcription noted after 24 h. Similar findings
have been described in VSMCs. The early AngII-induced
Smad activation is TGF-b independent,10 whereas the late
effect is mediated by TGF-b.21
There are several Smads proteins. Smad2 and Smad3 are
specific mediators of TGF-b/activin pathways, whereas
Smad1, Smad5, and Smad8 are involved in bone morpho-
genetic protein signaling.6 Smad3 is critical for EMT in
models of kidney injury and in aggressive carcinoma
metastasis.5,14 Smad3 and Smad2 have different roles in
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stimulated for 18 and 24 h. (a) Vimentin expression as mean±s.e.m. of three western blot experiments. TGF-b is involved in EMT and
morphological changes observed after 3 days of AngII treatment. (b) Vimentin expression as mean±s.e.m. of three western blot
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Figure 8 | Smad is involved in AngII-induced EMT. HK2 cells were transiently transfected with Smad7 expression vector or empty vector
(pcDNA3B). Then, cells were stimulated with AngII or TGF-b for (a) 24 h and (b) 3 days (b). (a) Data of total vimentin protein levels as
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TGF-b-induced EMT. The regulation of connective tissue
growth factor (CTGF) and E-cadherin expression are Smad3
dependent, whereas MMP-2 is regulated by Smad2. Both
Smad2 and Smad3 regulate a-SMA.5 In VSMCs, Smad3 is
involved in AngII-mediated vascular fibrosis.21 Our data
show that AngII activates Smad2/3 proteins in the kidney and
cultured renal cells, showing a similar pathway than TGF-b.
There is a cross-talk between MAPKs and Smad.6 Over-
expression of constitutively active members of the ras/MEK/
ERK cascade promotes Smad3-dependent processes in kidney
mesangial cells, while blocking the nuclear accumulation of
Smads in epithelial cells.25 In VSMC, AngII activates Smad
pathway via MAPKs activation.10,21 In HK2 cells, we have
found that all three MAPK inhibitors (p38, ERK, and JNK)
significantly diminished AngII-induced Smad2 phosphoryla-
tion. Future studies are needed to elucidate the interactions
between Smad and MAPK signaling in vivo in the kidney.
Rats that have been AngII-infused for 2 weeks presented
mild tubular damage, as described,16,17 and induction
of EMT, shown by a-SMA upregulation and downregulation
of E-cadherin. Several data in experimental models of
renal injury also indicate that AngII participates in vivo in
the EMT process.16 Evidences of EMT have also been
reported in human diabetic and nondiabetic progressive
nephropathies. In these renal pathologies, upregulation of
renal renin–angiotensin system and tubular myofibroblast
activation have been described.18,26 We have demonstrated
that, in cultured human tubuloepithelial cells, AngII causes
suppression of E-cadherin and de novo vimentin and a-SMA
expression, leading to the loss of epithelial cell adhesion and
the change from epithelial to fibroblast-like morphology,
suggesting a transitional phase in the dynamic phenomenon
of EMT, confirming previous data.15 TGF-b is a key factor
in renal EMT, by initiating and regulating the entire
process.7,11,27 We have compared the effect of AngII with
that of TGF-b. After 24 h of incubation, AngII induced
vimentin and a-SMA production and suppression of
E-cadherin, showing a similar early regulation of EMT
markers to that observed with TGF-b. The presence of
fibroblast-like cells was found at 3 days, with more positive
cells at 5 days, but without differences between AngII and
TGF-b, suggesting that both factors have a similar effect on
EMT. We have further investigated whether TGF-b mediates
AngII-induced EMT. In human tubuloepithelial cells, the
induction of vimentin production at 18 h of incubation with
AngII was not diminished by TGF-b blockers, showing that
early EMT caused by AngII is TGF-b independent. However,
the TGF-b blockade diminished the phenotypic conversion
to fibroblast-like morphology and induction of vimentin
after 3 days, showing that endogenous TGF-b production
participates in long-term EMT. Systemic AngII infusion
elicited changes in EMT markers after 2 weeks. At this time,
Smad activation and TGF-b upregulation were also found,
indicating that, in chronic infusion of AngII, the activation of
Smad pathway by endogenous TGF-b could contribute to
renal damage progression.
Transforming growth factor-b promotes EMT by several
mechanisms, with Smad pathway being the most relevant.
Our in vitro studies, blocking the Smad pathway by transient
transfection with Smad7, which interfere with activation of
Smad2 and Smad3, demonstrate that Smad pathway
participates in AngII-induced EMT. Thus, in cultured
tubuloepithelial cells, Smad7 overexpression prevented
vimentin and a-SMA induction and the transition to
fibroblast-like morphology caused by AngII. In different
animal models, including unilateral ureteral obstruction and
experimental hypertension, Smad7 overexpression attenuates
renal fibrosis.28 The same has been observed in animal
models of peritoneal fibrosis induced by peritoneal dialysis,
where Smad7 overexpression inhibited fibrosis.29,30 Different
therapies to interfere with TGF-b, including neutralizing
antibodies, antisense oligonucleotides, and decorin, have
been shown to diminish renal fibrosis. However, these
treatments cannot be used in humans. Renin–angiotensin
system blockers are commonly used in human renal diseases
with proven end-organ protective effects.3 The use of AngII
blockers, besides inhibiting AngII actions, also interfere with
TGF-b/Smad signaling, providing an important tool to
hinder TGF-b and prevent the loss of functional renal tissue.
Our results show that AngII activates the Smad signaling
system by a TGF-b-independent process in the kidney, both
in vivo and in vitro. We have also found that Smad proteins
participate in AngII-induced EMT. This novel finding
suggests that Smad activation could participate in AngII-
mediated profibrogenic effects in renal diseases.
MATERIALS AND METHODS
Experimental studies
Systemic infusion of AngII (in saline) was done into male Wistar
rats of 3 months of age (subcutaneous osmotic minipumps, Alza
Corp., CA), at 100 ng/kg/min for different times (from 24 h to
2 weeks; n¼ 4–8 animals per group). A control group of saline-
infused rats of the same age was also studied (n¼ 8 animals). The
kidneys were perfused in situ with cold saline before removal. One
kidney was fixed, embedded in paraffin, and used for immunohisto-
chemistry, and the other kidney was snap-frozen in liquid nitrogen
for RNA and protein studies (done in renal cortex). All experimental
procedures were approved by the Animal Care and Use Committee
of our Institution, according to the guidelines for ethical care of the
European Community.
Cell cultures
HK2 cells were grown in RPMI with 10% fetal bovine serum, 1%
nonessential amino acids, 100 U/ml penicillin, and 100 mg/ml
streptomycin, ITS, and hydrocortisone in 5% CO2 at 371C. At
60–70% of confluence, the cells were growth-arrested in a serum-free
medium for 24 h before the experiments. AngII (107 mol/l) was
added each day, and the medium and all stimuli were replaced every
48 h. Cell culture reagents were obtained from Life Technologies Inc.
and AngII was obtained from Bachem. The inhibitors used were
PD98059, ERK1/2 inhibitor, SB203580, p38 MAPK inhibitor, and
SP600125, JNK-1,-2,-3 inhibitor from Stressgen Bioreagents Corp.
(Victoria, BC, Canada). None of the inhibitors were toxic at the
doses used (evaluated by cell viability assay microculture tetrazoluin
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assay, Promega). Antibodies employed were a-SMA (Sigma
Chemical Co., St Louis, MO, USA); vimentin (BD Pharmingen,
San Diego, CA, USA), E-cadherin (R&D Systems, Minneapolis, MN,
USA), Smad2, Smad4, phosphorylated Smad2/3 (Sta. Cruz Bio-
technology, Sta. Cruz, CA, USA), pSmad2 (Cell Signaling Techno-
logy, Danvers, MA, USA), pSmad3 kindly donated by Dr Leof
(Mayo Clinic, Baltimore), TGF-b (ABCam, Cambridge, UK), and
secondary antibodies (Amersham, Buckinghamshire, UK).
Protein studies
To quantify protein levels, western blot was done.10,31 Protein
content was determined by BCA method (Pierce Biotechnology,
Rockford, IL, USA). The efficacy of protein loading and transfer to
membranes was assessed by a-tubulin, GAPDH, and Ponceau S
staining.
Immunocytochemistry was performed in cells growing in
coverslips, fixed, treated with 0.1% Triton X-100, incubated with
primary antibodies, followed by fluorescein isothiocyanate-conju-
gated antibodies.10 Nuclei were stained with 1 mg/ml propidium
iodide. Samples were mounted in Mowiol 40–88 and examined by a
laser scanning confocal microscope (Leika).
Immunohistochemistry was done in paraffin-embedded renal
sections.18 Renal sections of 4 mm were deparaffinized, rehydrated,
their endogenous peroxidase was blocked and incubated with
primary antibody (overnight, 41C), followed by incubation with the
corresponding secondary antibody, and revealed by standard
techniques. The specificity was checked by the omission of primary
antibody and use of nonimmune sera (not shown).
Gene studies
Total RNA was isolated with Trizol (Gibco, Invitrogen, Carlsbad,
CA, USA) and gene expression was analyzed by real-time
PCR, performed on an ABI Prism 7500 sequence detection PCR
system (Applied Biosystems, Foster City, CA) according to the
manufacturer’s protocol. Assay IDs used are TGF-b:Rn00572010_m1,
thromsbospondin-1: Rn01513693_m1, Smad4;Rn00570593_m1, Smad7;
Rn00578319_m1, a-SMA:Rn00570060_g1, E-cadherin:Rn00580109_m1,
and vimentin:Rn0059738_m1. For normalized data, different approaches
were done using several housekeeping genes, including GAPDH,
Histone-3, and 18s ribosomal RNA expression (assay IDs:
Rn99999916_m1 and Hs99999901_s). Each animal was evaluated
independently by duplicate, and data were expressed as mean±s.e.m.
of eight animals per group as n-fold increase vs control group.
Analysis of Smad DNA-binding activity
Smad DNA-binding activity was determined in 6 mg nuclear extracts
as described,10 by binding with radioactive labeled consensus
CAGA-box oligonucleotide (50-TCGAGAGCCAGACAAAAAGCCA
GACATTTAGCCAGACAC-30, Sta. Cruz), and complexes were
analyzed by electrophoretic mobility shift assay. Competition assays
were done with a 100-fold excess of unlabeled or mutant oligo-
nucleotide (50-TCGAGAGCTAGATAAAAAGCTAGATATTAGCTAG
ATAC-3).
Southwestern histochemistry was used for Smad detection as
described,18 including controls and the Smad binding consensus
sequence (50-GAGTATGTCTAGACTGACAATGTAC-30).
Transfection, DNA constructs, and promoter studies
HK2 cells in fetal bovine serum were transiently transfected for 18 h
with FuGENE (Roche Molecular Biochemicals, Indianapolis, IN,
USA) and PcDNA3-FLAG-Smad7 expression vector (kindly donated
by Dr Massague´, Memorial Sloan-Keternig Cancer Center,
New York, USA) or empty vector (pcDNA3B). Cells were growth-
arrested for 24 h before experiments. To demonstrate Smad7
transfection efficacy, an anti-FLAG antibody was used (not shown).
Smad-dependent promoter activation was evaluated by transfection
of Smad/luc (kindly donated by Dr Volgestein, Baltimore, MD,
USA) and TK-renilla as internal control, as described.10
Statistical analysis
Histochemistry was quantified by image analysis using a KZ 300
imaging system 3.0. (Zeiss, Munchen-Hallbergmoos, Germany). For
immunohistochemistry, the percentage of the stained area was
calculated as the ratio of stained area vs total field area, and staining
score is expressed as density/mm2. For Southwestern histochemistry,
positive cells were counted and expressed as number of Smad
positive cells/mm2. For each sample, the mean data was obtained by
analysis of 20 different fields ( 200). These experiments were
performed in two kidney sections per experimental animal to obtain
a mean score for each of them. In all cases, evaluations were
performed by two independent observers in a blinded fashion, and
the mean score value was calculated for each rat.
The autoradiographs were scanned using the GS-800 Calibrated
Densitometer (Quantity One, Bio-Rad, Hercules, CA, USA). Results
are expressed as n-fold increase over control as mean±s.e.m.
Equality of variances was tested with Levene’s test. Normally
distributed continuous variables with equal variances were analyzed
with analysis of variance, otherwise with Kruskall–Wallis test. A
P valueo0.05 was considered significant. Tests were done using the
SPSS 11.5 software package.
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